Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

NCT: NCT06423430 · RECRUITING

NCT IDNCT06423430
StatusRECRUITING
Start Date2024-09-11
Completion2029-04

Brief Summary

The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) in adults.

Frequently Asked Questions

What is Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)?

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND) is a clinical trial registered under NCT06423430. Current status: RECRUITING.

What is the status of NCT06423430?

The current status of NCT06423430 (Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)) is: RECRUITING.

When did Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND) start?

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND) started on 2024-09-11.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑